Novo Nordisk A/S – Share repurchase programme

Core Viewpoint - Novo Nordisk has initiated a share repurchase program with a total value of up to DKK 20 billion, which will be executed over a 12-month period starting from February 6, 2024 [1][3]. Share Repurchase Program Details - The program initiated on May 6, 2024, includes a repurchase of B shares for an amount up to DKK 2.2 billion from May 7, 2024, to August 5, 2024 [1]. - As of July 26, 2024, Novo Nordisk has repurchased a total of 10,820,537 B shares at an average price of DKK 878.72 per share, amounting to a total transaction value of DKK 9,508,271,105 [3]. Transaction Summary - The accumulated number of B shares repurchased as of the last announcement is 1,884,787, with a total transaction value of DKK 1,799,046,117 [2]. - Specific transactions from July 22 to July 26, 2024, include: - July 22: 39,000 shares at an average price of DKK 909.36, total value DKK 35,465,111 - July 23: 41,000 shares at an average price of DKK 918.79, total value DKK 37,670,272 - July 24: 41,000 shares at an average price of DKK 909.74, total value DKK 37,299,164 - July 25: 40,000 shares at an average price of DKK 885.45, total value DKK 35,417,923 - July 26: 40,500 shares at an average price of DKK 879.94, total value DKK 35,637,745 [2]. Treasury Shares - Following the transactions, Novo Nordisk holds a total of 12,186,327 B shares as treasury shares, representing 0.3% of the total share capital [3]. - The total number of A and B shares in the company is 4,465,000,000, including treasury shares [3]. Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focusing on chronic diseases, particularly diabetes [4]. - The company employs approximately 66,000 people across 80 countries and markets its products in around 170 countries [4]. - Novo Nordisk's B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange [4].